Lepor H, Theune C
Department of Urology, New York University School of Medicine, New York, USA.
J Urol. 1995 Jul;154(1):116-8.
We attempt to determine whether terazosin is effective therapy for the treatment of prostatism-like symptoms in women.
A total of 29 women 47 to 79 years old with prostatism-like symptoms entered a randomized double-blind study comparing terazosin (14) versus placebo (15). The salient inclusion and exclusion criteria consisted of an American Urological Association (AUA) symptom score of 8 or more, post-void residual volume less than 300 ml. and absence of stress urinary incontinence.
The baseline and final visit AUA symptom scores were 12.7 and 10.7 respectively, in the placebo group, and 16.4 and 13.6, respectively, in the terazosin group. The differences between the change in AUA symptom score in the placebo and terazosin groups were not clinically or statistically significant.
Our study demonstrates that terazosin is not effective for the treatment of prostatism-like symptoms in aging women.
我们试图确定特拉唑嗪是否是治疗女性前列腺增生样症状的有效疗法。
共有29名年龄在47至79岁之间有前列腺增生样症状的女性进入一项随机双盲研究，比较特拉唑嗪（14例）与安慰剂（15例）。主要的纳入和排除标准包括美国泌尿外科学会（AUA）症状评分8分或更高、排尿后残余尿量少于300毫升以及无压力性尿失禁。
安慰剂组基线和末次访视时的AUA症状评分分别为12.7和10.7，特拉唑嗪组分别为16.4和13.6。安慰剂组和特拉唑嗪组AUA症状评分变化之间的差异在临床或统计学上均无显著意义。
我们的研究表明，特拉唑嗪对治疗老年女性前列腺增生样症状无效。
